Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Katherine Harris, PhD

Multi-Specific Antibody Development Using Sequence-Based Antibody Discovery

TeneoBio Inc.

William Pardridge, M.D.

Brain Drug Delivery of Therapeutic Antibodies with Blood-Brain Barrier Penetrating Bi-Specific Antibodies:

UCLA / ArmaGen

Jun 20
Show Filter
7:00am - 8:15am 75 mins
Breakfast & Registration
8:15am - 8:45am 30 mins
KEYNOTE: Computational Drug Design
  • Possu Huang, PhD - Assistant Professor of Bioengineering, Stanford University
8:45am - 9:15am 30 mins
Utilising DNA Sequencing in Protein Therapeutics
  • How can molecular biotechnology be used in protein therapeutics?
  • How can it be used to find new targets?
  • What is the technology?
  • How can we use technology and DNA sequencing to advance these therapies?
9:15am - 9:45am 30 mins
Synthetic DNA Technologies Enable Antibody Discovery and Optimization
  • Aaron Sato, PhD - Chief Scientific Officer, Twist Bioscience

Utilizing it’s proprietary DNA writing technology to create oligo pools, genes, and synthetic libraries, Twist Pharma, a division of Twist Bioscience, provides the biotechnology industry with an end-to-end antibody discovery solution. This solution includes (1) a panel of high diversity synthetic antibody libraries, (2) a proprietary human anti-GPCR antibody phage display library focused on this validated target class, and (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization.

9:45am - 10:30am 45 mins
Networking Refreshments
10:30am - 11:00am 30 mins
Multi-Specific Antibody Development Using Sequence-Based Antibody Discovery
  • Katherine Harris, PhD - Senior Director of Discovery, TeneoBio Inc.

We have developed a novel, sequenced-based approach for the rapid and high-throughput discovery of antibodies from our human transgenic rat (UniRat) platform. UniRats express fully human heavy chain only antibodies called UniAbs. UniAbs are ideal building blocks for antibody-based biologics because they can be genetically fused to other proteins and can be arranged to make multi-specific antibodies without the complication of heavy and light chain pairing. Our results show UniAbs have biochemical properties similar to conventional antibodies and have distinct advantages for developing next-generation multi-specific therapeutic antibodies.

11:00am - 11:30am 30 mins
PANEL DISCUSSION: Identifying New Targets
  • Mike Schopperle, PhD - CEO, CureMeta
  • Katherine Harris, PhD - Senior Director of Discovery, TeneoBio Inc.
  • Methods & Technologies used to identify new targets within the body
  • Finding good tumour antigens to target
  • Non-tumour targeting
  • FAP located in tumour microenvironment
  • IL-10 and fibronectin
  • Genome Sequencing
  • GPCRs
11:30am - 12:00pm 30 mins
Bi-Specific Antibodies - Platform Approaches To Rapidly Generate Binder & Format Variability:
  • Ulrich Brinkmann, Ph.D. - Expert Scientist, Large Molecule Research, Pharma Research & Early Development, Roche Innovation Center, Munich
12:00pm - 1:00pm 60 mins
1:00pm - 1:30pm 30 mins
Immunoglobulin Domain Interface Exchange as a Platform Technology To Engineer and Manufacture Bispecific Antibodies
  • Stanislas Blein, Ph.D., - Senior Director, Head Antibody Engineering, Glenmark Biotherapeutics

Glenmark Pharmaceuticals’ BEAT® platform is a robust and versatile bispecific antibody platform based on heavy chain heterodimerization. The technology relies on biomimicry wherein the protein-protein interfaces of two different immunoglobulin constant domain pairs are exchanged to design new heterodimeric CH3 domains. In transient transfections, at equimolar chain ratios, engineering allows for ≥ 95% heterodimerization in the bispecific Fab  scFv and the Fab  Fab common light chain antibody formats. Using our platform, we have engineered and in-house manufactured two clinical stage bispecific antibodies. Engineering concept, manufacturing, and latest improvements to the platform will be presented.

1:30pm - 2:00pm 30 mins
Brain Drug Delivery of Therapeutic Antibodies with Blood-Brain Barrier Penetrating Bi-Specific Antibodies:
  • William Pardridge, M.D. - Distinguished Professor Emeritus / Founder and CSO, UCLA / ArmaGen
  • Technology and Bi-specific designs capable of passing through BBB.
  • Overcoming the challenges with targeting brain cancers
2:00pm - 2:30pm 30 mins
Entering The Cell: How To Carry Out Intracellular Delivery
  • Methods for intracellular delivery
  • Techniques for intracellular delivery
  • Technologies for intracellular delivery
  • The best protein therapeutics for intracellular needs of diseases
2:30pm - 3:00pm 30 mins
Networking Refreshment Break
3:00pm - 3:30pm 30 mins
Generation of a Bi-specific ADAPTIR Molecule that Targets CD86 and Delivers IL-10 Inhibits Antigen Presenting Cells and Has Potential as a Therapeutic Treatment of Autoimmune Disease
  • Gabriela Hoyos - Senior Director, Immunobiology, Aptevo Therapeutics

IL-10 is a key negative regulator of inflammation, however, development of IL-10 in the clinic for suppression of inflammation has been challenging. APVO210, an anti-CD86 scFv x monoIL10 fusion, offers key advantages over other IL-10 based drugs, due to its unique MOA: selective stimulation of the IL-10R on APC, without stimulating T and B cells. Potent biological activity has been demonstrated preclinically in vivo.

3:30pm - 4:00pm 30 mins
The Development of Innovative Therapeutics for Oncology
  • Eugene Zhukovsky, Ph.D. - Chief Scientific Officer, Research, Biomunex Pharmaceuticals
  • Bi-Specific Antibodies, Checkpoint Inhibitors and developing new therapeutic designs
  • How can they be improved?
  • Preventing CRS when using various next generation protein therapeutics e.g. checkpoint inhibitors
  • Describing approaches in terms of maintaining efficacy and cytotoxicity and reducing CRS
  • Other side effects which can be caused and how these can be reduced
  • How to cope with undiscovered side effects?
4:00pm - 4:30pm 30 mins
PANEL DISCUSSION: What is The Best Protein Therapeutic?
  • Nathan Trinklein, PhD - Chief Technology Officer, Teneobio, Inc.
  • Paul Moore, Ph.D. - Vice President, Immunology & Cell Biology, MacroGenics
  • Comparison of mAbs, antibody fragments and alternative scaffolds at combating solid tumours.
  • The perspective of a physician
  • What does industry need to know to sell the drug?
  • What do Doctors look for in Next Generation Therapeutics?
4:30pm - 4:35pm 5 mins
End of Next Generation Protein Therapeutics and Bioconjugates Summit 2019